Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 12, Pages 1980
Publisher
MDPI AG
Online
2019-12-10
DOI
10.3390/cancers11121980
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Exploring and comparing adverse events between PARP inhibitors
- (2019) Christopher J LaFargue et al. LANCET ONCOLOGY
- Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
- (2019) Zebin Wang et al. Scientific Reports
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019
- (2019) Margaret A. Tempero et al. Journal of the National Comprehensive Cancer Network
- An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.
- (2019) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.
- (2019) E. Gabriela Chiorean et al. JOURNAL OF CLINICAL ONCOLOGY
- Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC).
- (2019) Michael J. Pishvaian et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy.
- (2019) Kim Anna Reiss et al. JOURNAL OF CLINICAL ONCOLOGY
- Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial.
- (2019) Anup Kasi et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
- (2019) Alexandra S. Zimmer et al. Journal for ImmunoTherapy of Cancer
- Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
- (2018) Maeve A. Lowery et al. EUROPEAN JOURNAL OF CANCER
- Abstract 337: The PARP inhibitor olaparib is synergistic with the ATR inhibitor AZD6738 in ATM deficient cancer cells
- (2018) Rebecca Lloyd et al. CANCER RESEARCH
- TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.
- (2018) Shaveta Vinayak et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).
- (2018) Laetitia Dahan et al. JOURNAL OF CLINICAL ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
- (2017) Chaoyang Sun et al. Science Translational Medicine
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
- (2017) Brian A. Dougherty et al. Oncotarget
- BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
- (2016) M. Moschetta et al. ANNALS OF ONCOLOGY
- The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
- (2016) L. Oplustil O'Connor et al. CANCER RESEARCH
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
- (2016) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
- (2016) Yi Du et al. NATURE MEDICINE
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1 -Mutant Ovarian Cancer
- (2016) Young Eun Choi et al. Cell Reports
- CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
- (2016) Shawn F. Johnson et al. Cell Reports
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
- (2015) J. Bendell et al. ANNALS OF ONCOLOGY
- Identification of germline genetic mutations in patients with pancreatic cancer
- (2015) Erin E. Salo-Mullen et al. CANCER
- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
- (2015) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer
- (2015) Julia Carnevale et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
- (2015) Spring Holter et al. JOURNAL OF CLINICAL ONCOLOGY
- A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition
- (2015) D. A. Alagpulinsa et al. MOLECULAR CANCER THERAPEUTICS
- Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance
- (2015) Peter Bai MOLECULAR CELL
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
- (2015) T. Higuchi et al. Cancer Immunology Research
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
- (2014) T Golan et al. BRITISH JOURNAL OF CANCER
- Non-homologous end joining: Emerging themes and unanswered questions
- (2014) Sarvan Kumar Radhakrishnan et al. DNA REPAIR
- Role of AKT signaling in DNA repair and clinical response to cancer therapy
- (2014) Q. Liu et al. NEURO-ONCOLOGY
- Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888
- (2014) Richard Tuli et al. Translational Oncology
- Interferon- Suppresses cAMP to Disarm Human Regulatory T Cells
- (2013) N. Bacher et al. CANCER RESEARCH
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Identification of miRNA modulators to PARP inhibitor response
- (2013) Sari Neijenhuis et al. DNA REPAIR
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural Implications for Selective Targeting of PARPs
- (2013) Jamin D. Steffen et al. Frontiers in Oncology
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
- (2012) Lenka Oplustilova et al. CELL CYCLE
- Type I IFN Drives a Distinctive Dendritic Cell Maturation Phenotype That Allows Continued Class II MHC Synthesis and Antigen Processing
- (2012) D. P. Simmons et al. JOURNAL OF IMMUNOLOGY
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity
- (2012) Letizia Porcelli et al. Molecular Oncology
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts
- (2012) Cindy Neuzillet WORLD JOURNAL OF GASTROENTEROLOGY
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Synthetic lethality of PARP inhibition in cancers lackingBRCA1andBRCA2mutations
- (2011) Konstantin J. Dedes et al. CELL CYCLE
- The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
- (2011) D. Blazek et al. GENES & DEVELOPMENT
- Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes
- (2011) Anand G. Patel et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway
- (2010) Michael R. Lieber Annual Review of Biochemistry
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling
- (2010) Robert R McWilliams et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
- (2010) Raga Krishnakumar et al. MOLECULAR CELL
- Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis
- (2010) Mary Ellen Moynahan et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Susceptibility Pathways in Fanconi's Anemia and Breast Cancer
- (2010) Alan D. D'Andrea NEW ENGLAND JOURNAL OF MEDICINE
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2009) C Yoo et al. BRITISH JOURNAL OF CANCER
- Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity
- (2009) D. Melisi et al. CLINICAL CANCER RESEARCH
- Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity
- (2009) T. D. Pfister et al. MOLECULAR CANCER THERAPEUTICS
- A Selective Requirement for 53BP1 in the Biological Response to Genomic Instability Induced by Brca1 Deficiency
- (2009) Liu Cao et al. MOLECULAR CELL
- STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
- (2009) Hiroki Ishikawa et al. NATURE
- Poly(ADP-ribose)-Dependent Regulation of DNA Repair by the Chromatin Remodeling Enzyme ALC1
- (2009) D. Ahel et al. SCIENCE
- Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
- (2009) S. Jones et al. SCIENCE
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- BRCAGermline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
- (2008) Cristina R. Ferrone et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes
- (2008) Jean-Philippe Gagné et al. NUCLEIC ACIDS RESEARCH
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation